We are saddened to share that in the past week, the EHC has been informed of the death of a person with haemophilia with inhibitors, who was on the clinical trial (HAVEN 1) with the bi-specific antibody Emicizumab.

We requested information from Roche, the company carrying out the clinical trial, about this case and received the following response:

Dear members of the European Haemophilia Consortium,

At Roche, we respect and value the close relationships that exist within the haemophilia community. We also understand the important role patient organizations play within it. As such, we would like to officially update you on recent events in our HAVEN 1 study.

HAVEN 1 is the ongoing phase III study investigating the safety and efficacy of emicizumab in people 12 years of age or older, with haemophilia A and factor VIII inhibitors.

As part of our standard process to receive and expedite the reporting and investigating of adverse drug events (AEs), we received two new reports of Serious Adverse Events (SAE) in a patient who was enrolled in the HAVEN 1 study. Unfortunately, we were informed that the patient passed away. We are deeply saddened by this information.

The HAVEN 1 trial is ongoing, and thus the amount of information we have and can share is limited in order to protect the integrity of an ongoing study. Below is a brief summary of the medical history.

It is our understanding that a patient experienced a serious rectal haemorrhage (first reported SAE) and received bypassing agents, including repeated doses of activated prothrombin complex (aPCC), after which the patient developed signs of Thrombotic Microangiopathy (TMA) (second SAE).

The preliminary assessment is that the clinical and laboratory characteristics of this case of TMA are consistent with what was observed in the two previously reported cases; however, our evaluation of the available information is ongoing.

After aPCC was discontinued, laboratory values associated with TMA (platelet count and LDH) were improving.

According to the report, treatment of the haemorrhage was complicated because the patient declined blood transfusions.

The investigator’s assessment is that the cause of death was the rectal haemorrhage, and that this is not related to emicizumab.

Based on the available details of the case and our initial assessment, we believe our current protocol guidance in the trial regarding the use of bypassing agents remains appropriate. This guidance includes the recommendation to avoid the use of aPCC, if possible, as well as to use the lowest doses of approved bypassing agents in patients receiving emicizumab. We are continuing to investigate the details of this patient case and we will update any guidance as appropriate.



We have developed our guidance in consultation with our independent data monitoring committee (IDMC), which includes highly respected

scientific and clinical haemophilia experts.

We will be evaluating the information from this particular case in the context of the other information from our on-going clinical trials.

We look forward to presenting data from the HAVEN 1 study of emicizumab in people with haemophilia A and inhibitors to factor VIII, which will provide better

context for the overall benefit/risk profile of emicizumab in this patient population, at an upcoming medical conference.

For all of us at Roche, patient safety continues to be of paramount importance. We will continue to work closely with the IDMC, Steering Committee, and our Investigators to evaluate all safety events that have been observed and to ensure the proper measures are in place to assure continued patient safety.

Meantime, we would recommend that all questions related to the above safety events be referred to the Roche affiliate in your respective country. Questions from patients participating in an emicizumab clinical trial should be referred to the relevant study investigator.

The EHC expresses condolences to the family.